Pittsburgh Compound B-Negative Dementia—A Possibility of Misdiagnosis of Patients With Non-Alzheimer Disease-Type Dementia as Having AD

Abstract

Amyloid imaging has been used to detect amyloid deposition in the brain. We performed Pittsburgh compound B (PiB)-positron emission tomography on 63 patients with dementia having cognitive decline or memory disturbance. In addition, we measured the patients' apolipoprotein E4 (apo E4) status and cerebrospinal fluid (CSF) levels of amyloid-β (Aβ)1-42, tau, and P-tau. Finally, the patients were diagnosed as having probable Alzheimer disease (AD) on the basis of their neuropsychological findings and because they met the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer’s Disease and Related Disorders Association criteria. Among the patients diagnosed with probable AD, 10 patients were PiB negative. The CSF levels of P-tau and tau in PiB-negative patients were significantly lower than those in the PiB-positive patients. In addition, the CSF levels of Aβ1-42 in the PiB-negative patients were significantly higher than those in the PiB-positive patients. None of the PiB-negative patients were apo E4 carriers. These results suggest that the PiB-negative patient group included not only AD patients but also non-AD-type dementia patients. However, our finding is based on a relatively small number of patients and therefore should be replicated in a larger cohort. In addition, it will be necessary to categorize these participants by longitudinal follow-up and postmortem pathological examinations.

Keywords

PiB-PET PiB-negative dementia CSF biomarkers non-AD type dementia

Get full access to this article

View all access options for this article.

References

Klunk

Engler

Nordberg

. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004;55(3):306–319.

Kemppainen

Aalto

Wilson

. PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment. Neurology. 2007;68(19):1603–1606.

Klunk

Wang

Huang

. The binding of 2-(4'-methylaminophenyl)benzothiazole to postmortem brain homogenates is dominated by the amyloid component. J Neurosci. 2003; 23(6):2086–2092.

Rowe

Ackermann

. Imaging beta-amyloid burden in aging and dementia. Neurology. 2007;68(20):1718–1725.

Lopresti

Klunk

Mathis

. Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med. 2005;46(12):1959–1972.

Cairns

Ikonomovic

Benzinger

. Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report. Arch Neurol. 2009; 66(12):1557–1562.

Rosen

Ciliax

Wingo

. Deficient high-affinity binding of Pittsburgh compound B in a case of Alzheimer’s disease. Acta Neuropathol. 2009;119(2):221–233.

Tomiyama

Nagata

Shimada

. A new amyloid mu variant favoring oligomerization in Alzheimer’s-type dementia. Ann Neurol. 2008;63(3):377–387.

McKeith

Dickson

Lowe

. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005;65(12):1863–1872.

10.

Piguet

Halliday

Creasey

Broe

Kril

. Frontotemporal dementia and dementia with Lewy bodies in a case-control study of Alzheimer's disease. Int Psychogeriatr. 2009;21(4):688–695.

11.

Steuerwald

Baumann

Taylor

. Clinical characteristics of dementia associated with argyrophilic grain disease. Dement Geriatr Cogn Disord. 2007;24(3):229–234.

12.

Togo

Isojima

Akatsu

. Clinical features of argyrophilic grain disease: a retrospective survey of cases with neuropsychiatric symptoms. Am J Geriatr Psychiatry. 2005;13(12):1083–1091.

13.

Bancher

Jellinger

. Neurofibrillary tangle predominant form of senile dementia of Alzheimer type: a rare subtype in very old subjects. Acta Neuropathol. 1994;88(6):565–570.

14.

Jellinger

Attems

. Neurofibrillary tangle-predominant dementia: comparison with classical Alzheimer disease. Acta Neuropathol. 2007;113(2):107–117.

15.

Holmes

Boche

Wilkinson

. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet. 2008; 372(9634):216–223.